Understand the meaning and implications of polypharmacy and the issues it causes for patient adherence; Discover policies, technologies and procedures that can eliminate or reduce the effects of polypharmacy ensuring quality outcomes; Highlight issues Pharmacist Partners, as an organization, has remedied and the technology they utilize to decrease overuse or underuse of medication
Ten state governors seeking to avoid millions of dollars in federal healthcare cuts under Republican plans to replace Obamacare pressed their case in a meeting with Vice President Mike Pence, according to two people briefed on the talks.
Herbal medications offer few benefits and many risks for people with heart disease, according to a recent review.
PTC Therapeutics Inc. said it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.
Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union
The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under this agreement, U.S. and EU regulators will be able to utilize each other’s good manufacturing practice inspections of pharmaceutical manufacturing facilities.
Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area’s GRAIL Banks $900 Million
Grail Inc., a company focused on using diagnostics to develop early-stage cancer detection, bagged $900 million in Series B financing.
Citing a recent evaluation of the orphan drug market by Evaluate, Endpoints picked 10 orphan drug candidates that could, if approved, become blockbusters, or near blockbusters, by 2022.
Juno pulled the plug on its once-promising lead CAR-T cancer treatment JCAR015.
Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.
South Korea said it has fined Swiss drugmaker Novartis 200 million won ($174,937) and temporarily banned sales of some of its drugs for paying kickbacks to doctors in exchange for recommending the company’s drugs.